Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China
Open Access
- 1 February 2023
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 443-451
- https://doi.org/10.2147/ccid.s396997
Abstract
Background: The Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) are important evaluation tools for assessing psoriasis severity and guiding treatment options. However, the scores of PASI and DLQI are often inconsistent. Objective: This study aimed to identify the factors affecting the consistency between PASI and DLQI. Methods: The retrospective study was based on 4125 patients. We collected the PASI, DLQI, demographic and clinical characteristics data. Results: DLQI has a weak correlation with PASI (r=0.37; P< 0.001). For the DLQI > 10 groups, DLQI has almost no correlation with PASI (r=0.16; P< 0.001). There are 43.60% of mild-to-moderate patients (PASI< 10) in the DLQI> 10 groups. Our adjusted model showed that foot (OR=2.109; 95% CI:1.581– 2.815) involvement led to the greatest impairment of QoL except for PASI≥ 10 (OR=5.547; 95% CI:3.477– 8.845). Furthermore, DLQI impairment was associated with female (OR=1.336; 95% CI:1.071– 1.667); the age of 20– 39 subgroup (OR=1.795; 95% CI:1.100– 2.930); psoriatic arthritis (OR=1.718; 95% CI:1.208– 2.443); higher income (OR = 1.408; 95% CI: 1.067– 1.858); family history of psoriasis (OR=1.460; 95% CI:1.131– 1.885). Moreover, the influence of exposed lesions (such as scalp; face; neck; nails; and hands) were positively associated with severely impaired QoL. Conclusion: Dermatologists should recognize the underestimated disease burden of psoriasis patients and actively identify and treat mild-to-moderate patients with high burden. In particular, the foot was a significant contributor to the burden.Keywords
This publication has 33 references indexed in Scilit:
- Eficacia y seguridad en terapia con psoralen-UVA (PUVA) tópica en psoriasis palmoplantar. Experiencia en una serie de 48 pacientesActas Dermo-Sifiliograficas, 2013
- Psychometric properties of the Chinese version of dermatology life quality index (DLQI) in 851 Chinese patients with psoriasisJournal of the European Academy of Dermatology and Venereology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchiv für dermatologische Forschung, 2010
- Key principles for the improved conduct of health technology assessments for resource allocation decisionsInternational Journal of Technology Assessment in Health Care, 2008
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- Rethinking the Psoriasis Area and Severity Index: the impact of area should be increasedBritish Journal of Dermatology, 2004
- The impact of psoriasis on quality of lifeBritish Journal of Dermatology, 2001
- The outcomes movement and new measures of the severity of psoriasisJournal of the American Academy of Dermatology, 1996
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994